STOCK TITAN
  1. Home
  2. News
  3. APYX

Apyx Medical Corporation - APYX STOCK NEWS

Welcome to our dedicated page for Apyx Medical Corporation news (Ticker: APYX), a resource for investors and traders seeking the latest updates and insights on Apyx Medical Corporation stock.

Apyx Medical Corporation (APYX) delivers innovative plasma-based energy systems for surgical and cosmetic applications. This news hub provides investors and medical professionals with timely updates on regulatory developments, product innovations, and strategic partnerships driving advancements in electrosurgical technology.

Access authoritative reporting on APYX's Advanced Energy segment developments, including Renuvion® system enhancements, and OEM manufacturing collaborations. Track financial performance updates, clinical study results, and market expansion initiatives critical to evaluating the company's position in medical device innovation.

Our curated news collection features earnings announcements, FDA clearances, research publications, and executive leadership changes. Stay informed about helium plasma technology applications in dermatology and general surgery through verified sources, maintained for accuracy and relevance.

Bookmark this page for streamlined access to APYX's evolving corporate narrative. Combine real-time updates with historical context to better understand this pioneer in energy-based surgical solutions.

News

Apyx Medical Corporation Reports Fourth Quarter and Full Year 2023 Financial Results; Introduces Full Year 2024 Financial Outlook

Rhea-AI Summary
Apyx Medical (APYX) reports a 15% increase in Advanced Energy sales year-over-year in the fourth quarter, with total revenue reaching $14.7 million. The company also introduces financial expectations for 2024, with a focus on managing resources efficiently and strategic investments.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-28.65%
Tags
earnings
-
News

Apyx Medical Corporation to Release Fourth Quarter and Fiscal Year 2023 Financial Results on March 21, 2024

Rhea-AI Summary
Apyx Medical Corporation (APYX) to release financial results for Q4 and FY 2023 on March 21st, with a conference call to discuss the outcomes.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.4%
Tags
earnings
-
News

Apyx Medical Corporation Announces Renuvion to be Featured in Educational Sessions at the American Academy of Cosmetic Surgery (AACS) Scientific Meeting

Rhea-AI Summary
Apyx Medical Corporation announces that its Renuvion technology will be featured in educational sessions at the American Academy of Cosmetic Surgery’s 40th Annual Scientific Meeting. Dr. Michael Kluska will present results of a clinical study showing fewer adverse events with Renuvion compared to a competing technology in liposuction and body contouring procedures.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-6.48%
Tags
none
News

Apyx Medical Corporation Announces Peer-Reviewed Clinical Publication Evaluating the Safety of Renuvion® Following Liposuction in Multiple Areas of the Body

Rhea-AI Summary
Apyx Medical Corporation announced the publication of a peer-reviewed article in the Aesthetic Surgery Journal Open Forum, which evaluated the use of Renuvion for contracting subcutaneous soft tissue following liposuction in multiple areas of the body. The analysis of data from 483 patients found no new or increased risks for any area of the body compared to the use of liposuction alone. The study demonstrated Renuvion's impressive safety when used after liposuction, which led to securing FDA 510(k) clearance for the use of Renuvion APR Handpiece. The authors concluded that the use of Renuvion following liposuction for any particular area of the body demonstrated no new or increased risks compared to published data for patients having liposuction performed alone.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
6.03%
Tags
none
-
News

Apyx Medical Corporation Reports Preliminary Fourth Quarter and Full Year 2023 Revenue Results

Rhea-AI Summary
Apyx Medical Corporation (NASDAQ:APYX) reported preliminary revenue results for the fourth quarter and full year ended December 31, 2023. Total revenue for Q4 2023 was approximately $14.2 to $14.6 million, representing 13% to 16% year-over-year growth. Full year 2023 revenue was approximately $51.9 to $52.3 million, showing 17% to 18% year-over-year growth.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.08%
Tags
none
-
News

Apyx Medical Corporation Announces New Debt Facility with Perceptive Advisors

Rhea-AI Summary
Apyx Medical Corporation (APYX) announced a new $45 million credit agreement with Perceptive Credit Holdings IV, LP, providing access to additional capital at more attractive terms. The facility includes senior, secured term loans, with an initial loan of $37.5 million fully drawn at closing. The agreement matures on November 8, 2028, with an initial loan of $37.5 million and a delayed draw loan of $7.5 million. The loans bear interest at a floating rate based on one-month SOFR, subject to a floor of 5.0%, plus 7.0%. The Perceptive Credit Agreement provides for 48 months of interest-only payments, with subsequent monthly payments of 3.0% of the outstanding balance. The obligations under the facility are secured by first priority liens on substantially all of the Company's assets. In connection with the initial loan, the Company issued Perceptive warrants to purchase up to 1,250,000 shares of its common stock.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-20.29%
Tags
none
News

Apyx Medical Corporation Reports Third Quarter 2023 Financial Results and Updates Full Year 2023 Financial Outlook

Rhea-AI Summary
Apyx Medical Corporation (NASDAQ:APYX) reported a 39% year-over-year increase in Q3 Advanced Energy sales, reaching $9.8 million. The Company also announced a new credit agreement and updated its financial expectations for the full year. The third quarter results showed a 31% year-over-year increase in total revenue to $12.0 million, with a net loss of $4.6 million. The updated guidance for 2023 includes a total revenue range of $53.0 million to $54.0 million, representing a 19% to 21% year-over-year growth.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-20.29%
Tags
earnings
-
News

Apyx Medical Corporation to Participate in Upcoming Investor Conferences in November

Rhea-AI Summary
Apyx Medical Corporation (NASDAQ:APYX) announced its participation in upcoming investor conferences, including the Stephens Annual Investment Conference, Craig-Hallum 14th Annual Alpha Select Conference, and Piper Sandler 35th Annual Healthcare Conference. Management will engage in fireside chats and 1x1 meetings, with audio webcasts available for replay on the company's investor relations website.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
conferences
-
News

Apyx Medical Corporation to Release Third Quarter of Fiscal Year 2023 Financial Results on November 9, 2023

Rhea-AI Summary
Apyx Medical Corporation will release its financial results for Q3 of fiscal year 2023 on November 9th. A conference call will be held to discuss the results and a webcast will be available. A telephonic replay will also be accessible.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-5.63%
Tags
earnings
News

Apyx Medical Corporation Reports Second Quarter 2023 Financial Results and Reaffirms Full Year 2023 Financial Outlook

Rhea-AI Summary
Apyx Medical Corporation reports Q2 2023 financial results, with total revenue of $13.6 million, up 32% YoY. Advanced Energy revenue increased 40% YoY to $11.7 million. Net loss attributable to stockholders decreased 82% YoY to $1.0 million. Company reaffirms financial guidance for full year 2023, expecting total revenue in the range of $59.0 million to $62.0 million, representing growth of approximately 33% to 39% YoY.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
20.1%
Tags
earnings
Stock APYX logo
Apyx Medical Corporation

Nasdaq:APYX

APYX Rankings

N/A Ranked by Market Cap
N/A Ranked by Dividends

APYX Stock Data

36.85M
32.14M
14.56%
45.84%
0.37%
Medical Devices
Surgical & Medical Instruments & Apparatus
Link
United States
CLEARWATER